American Society of Hematology

Figure 1

$Figure 1. Immature platelet fraction (IPF) for ITP patients and controls. (A) Baseline IPF percentage in healthy controls (n = 100) and ITP patient treatment episodes (n = 29). The y-axis represents percentage IPF; and the x-axis, individual treatment episodes. Every pretreatment percentage IPF for all 29 patient episodes with ITP was greater than any of the 100 normal controls. Mean percentage IPF for ITP patients, 28.2% ± 15.5% was greater than controls, 3.2% ± 1.4% (P < .01). (B) Baseline A-IPF in healthy controls (n = 100) and ITP patient treatment episodes (n = 29). The y-axis represents the A-IPF values; and the x-axis, individual treatment episodes. Only 4 of 29 ITP patient episodes before treatment had A-IPF greater than 4 × 109/L, to contrast to 93 of 100 controls. Mean A-IPF for ITP patients (n = 29), 2.8 ± 2.5 × 109/L was less than the controls (n = 100), 7.8 ± 3.1 × 109/L (P < .01).$

Immature platelet fraction (IPF) for ITP patients and controls. (A) Baseline IPF percentage in healthy controls (n = 100) and ITP patient treatment episodes (n = 29). The y-axis represents percentage IPF; and the x-axis, individual treatment episodes. Every pretreatment percentage IPF for all 29 patient episodes with ITP was greater than any of the 100 normal controls. Mean percentage IPF for ITP patients, 28.2% ± 15.5% was greater than controls, 3.2% ± 1.4% (P < .01). (B) Baseline A-IPF in healthy controls (n = 100) and ITP patient treatment episodes (n = 29). The y-axis represents the A-IPF values; and the x-axis, individual treatment episodes. Only 4 of 29 ITP patient episodes before treatment had A-IPF greater than 4 × 10⁹/L, to contrast to 93 of 100 controls. Mean A-IPF for ITP patients (n = 29), 2.8 ± 2.5 × 10⁹/L was less than the controls (n = 100), 7.8 ± 3.1 × 10⁹/L (P < .01).

This Feature Is Available To Subscribers Only